TRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared with malignant mesothelioma
| Autor: | Tomomi Fujii, Minami Matsuoka, Yuji Nitta, Sumire Sugimoto, Chiyoko Terada, Yohei Kishi, Tomoko Uchiyama, Kohei Morita, Ryuji Kawaguchi, Takahiko Kasai, Fumiaki Taniguchi, Maiko Takeda, Shoh Sasaki, Hiroe Itami, Fumi Okada, Chiho Ohbayashi, Tokiko Nakai |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Adenomatoid Tumor Adult L1 Adenomatoid tumor medicine.medical_treatment Uterus medicine.disease_cause Pathology and Forensic Medicine Diagnosis Differential 03 medical and health sciences 0302 clinical medicine medicine Biomarkers Tumor Humans Mesothelioma Mutation BAP1 business.industry Mesothelioma Malignant Immunosuppression Middle Aged medicine.disease Immunohistochemistry Tumor Necrosis Factor Receptor-Associated Peptides and Proteins 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Uterine Neoplasms Cancer research Female business |
| Zdroj: | Human pathology. 111 |
| ISSN: | 1532-8392 |
| Popis: | Summary Adenomatoid tumors (ATs) are benign mesothelial tumors with a good prognosis and usually occur in female and male genital tracts, including in the uterus. ATs are genetically defined by tumor necrosis factor receptor–associated factor (TRAF) 7 mutations, and a high number of AT cases show immunosuppression. On the other hand, malignant mesotheliomas (MMs) are malignant mesothelial tumors with a very poor prognosis. Genetic alterations in TRAF, methylthioadenosine phosphorylase(MTAP), and BRCA-associated nuclear protein 1 (BAP1) in ATs derived from the uterus and MMs of pleural or peritoneal origin were compared by gene sequence analysis or immunohistochemical approaches. Formalin-fixed paraffin-embedded tissues derived from patients were used for immunohistochemical staining of L1 cell adhesion molecule (L1CAM), BAP1, MTAP, and sialylated protein HEG homolog 1 (HEG1) in 51 uterine AT cases and 34 pleural or peritoneal MM cases and for next-generation sequencing of the TRAF7 gene in 44 AT cases and 21 MM cases. ATs had a significantly higher rate of L1CAM expression than MMs, whereas MMs had a significantly higher rate of loss of MTAP and BAP1 expression than ATs. There was no difference in the rate of HEG1 expression between the tumor types. Most of the ATs (37/44; 84%) had somatic mutations in TRAF7, but none of the MMs had somatic mutations in TRAF7 (0/21; 0%). In addition, a low number of AT cases were associated with a history of immunosuppression (9/51; 17.6%). TRAF7 mutation is one of the major factors distinguishing the development of AT from MM, and immunosuppression might not be associated with most AT cases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect